Skip to main content

Advertisement

Advertisement

US gives final approval of Pfizer's Covid vaccine for children aged 5-11

WASHINGTON — The United States can now start giving children aged 5-11 the Pfizer-BioNtech Covid vaccine, US health authorities said on Tuesday (Nov 2) in a move hailed by President Joe Biden as a "turning point" in the fight against the pandemic.

US gives final approval of Pfizer's Covid vaccine for children aged 5-11

Doses for children in the 5-11 age group have been procured and are beginning to ship them across the country.

WASHINGTON — The United States can now start giving children aged 5-11 the Pfizer-BioNtech Covid vaccine, US health authorities said on Tuesday (Nov 2) in a move hailed by President Joe Biden as a "turning point" in the fight against the pandemic.

Days after gaining authorisation from the Food and Drug Administration, the vaccine was endorsed by the Centres for Disease Control and Prevention, clearing the way for the vaccination of up to 28 million children.

The government was well ahead of the decision, procuring enough doses for the children in the 5-11 age group and beginning to ship them across the country. 

"Today, we have reached a turning point in our battle against Covid-19," Mr Biden said in a statement released by the White House.

Vaccinating younger children will "allow parents to end months of anxious worrying about their kids, and reduce the extent to which children spread the virus to others. It is a major step forward for our nation in our fight to defeat the virus”, the president continued.

The government has already secured enough vaccine for every child in America, he said, adding that over the weekend officials began the process of packing and shipping millions of doses. 

"The program will ramp up over the coming days, and (be) fully up and running during the week of November 8," he said.

The vaccine will still be given in two injections, three weeks apart. The dosage has been adjusted to 10 micrograms per injection, compared to 30 micrograms for the older age groups.

The caps on the children's vials will be orange, making them easily recognisable compared to the purple caps on the vials for older groups.

'MORE WORRIED' ABOUT COVID

The CDC had convened a panel of independent scientists on Tuesday to review the available data on the status of the outbreak in children, the effectiveness of Pfizer's vaccine, and its possible side effects during a day of live-streamed discussions. 

The panel unanimously recommended the vaccine, and the CDC then endorsed that recommendation.

The main concern was the risk of myocarditis, an inflammation of the heart muscle, detected in adolescents and young adults (mostly males) after vaccination with the Pfizer or Moderna shots. 

Health authorities have confirmed nearly 880 cases in people under 30 years of age, of which approximately 830 required hospitalisation. 

Nine deaths are suspected to have been related to myocarditis after the vaccine. 

But of six cases so far reviewed, vaccine-related myocarditis was ultimately not identified as the cause of death, paediatric cardiologist Matthew Oster said in a presentation. 

"I'm much more worried about what would happen to their child if they get Covid, for patients who don't have heart disease, than I am if they were to get this vaccine," he added. 

There have been more than 1.9 million cases of Covid-19 among five- to 11-year-olds in the United States, and more than 8,300 hospitalisations, more than 2,300 cases of MIS-C (paediatric multisystem inflammatory syndrome), and about 100 deaths. 

The expected benefits of vaccinating children also include fewer school closures, and a possible reduction in transmission of the epidemic into the general population.

According to a survey of 1,000 parents presented on Tuesday by the CDC, 57 per cent said they would "definitely" or "probably" get their child vaccinated.

"If I had a grandchild, I would certainly get that grandchild vaccinated as soon as possible," said Dr Beth Bell, an infectious disease specialist and committee member. 

"We have excellent evidence of efficacy and safety. We have a favourable risk benefit analysis." AFP

Related topics

Covid-19 coronavirus vaccine children Pfizer-BioNTech

Read more of the latest in

Advertisement

Popular

Advertisement

Stay in the know. Anytime. Anywhere.

Subscribe to get daily news updates, insights and must reads delivered straight to your inbox.

By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.

Aa